Equine Sports Council

Controlled Medications Library

ESC MEDICATION CLASSIFICATIONClass A - Therapeutic

ESC Medication Library · Revision 4

← Medication library · Compare sanctioning bodies

Pergolide,
Prasend

Medication Facts

Performance enhancing
Conditionally - Cushings
Total hours to clear
Not recorded
Frequently used
Most Prescribed
ESC ID
PERGOL-0695
Trade names
Permax
Drug type
Dopamine receptor agonist
Plasma half-life · hours
Not Published
Equine dosing
2 mcg/kg PO daily for treatment of Cushings -typically very small amounts. ***Avoid use with Acepromozine or any other sedatives/tranquilizers***
Cmax · peak plasma concentration
.01 to .03 ng/mL
Tmax · time to peak plasma concentration
1 to 2 hrs
ESC concentration guidance
.01 to .03 ng/ml
Primary withdrawal · hours
0
Washout withdrawal · hours
0
ESC control type
A1 - Generally Controlled - Therapeutic
Medication report required
Generally not required, however understand exceptions.

Uses & side effects

Inhibits ACTH hormone production & slows progression of Cushings

Drug interactions

Prascend (pergolide mesylate) has very few documented drug interactions, but it should never be given alongside dopamine antagonists (such as acepromazine). Because Prascend is a dopamine agonist used to treat Pituitary Pars Intermedia Dysfunction (PPID / Equine Cushing's Disease), medications that block dopamine receptors will directly counteract and neutralize its therapeutic effects.When managing a horse on Prascend, pay close attention to the following classes of medications and clinical risks:1. Dopamine Antagonists (Direct Contradiction)Do not administer Prascend concurrently with drugs that block dopamine pathways. These combinations diminish or completely eliminate the effectiveness of the pergolide treatment:Phenothiazine Sedatives: Acepromazine, a very common tranquilizer used in equine medicine.Gastrointestinal Motility Agents: Domperidone (often used for fescue toxicosis) and metoclopramide.2. Highly Protein-Bound DrugsPrascend is approximately 90% bound to plasma proteins. Use caution when co-administering it with other highly protein-bound medications, as they can compete for binding sites and alter circulating drug concentrations:Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Common equine NSAIDs like phenylbutazone ("bute") or flunixin meglumine (Banamine).While these are frequently prescribed together in older arthritic horses with PPID, your veterinarian should monitor the horse closely for heightened drug sensitivities or side effects.3. Reproductive and Hormonal RisksPergolide acts on the pituitary gland and suppresses the hormone prolactin. While not a strict drug-to-drug interaction, it heavily interferes with necessary maternal hormones:Lactating and Pregnant Mares: Prascend can stop colostrum and milk production. It should only be used in breeding animals if explicitly directed by a vet after weighing the risks.4. Ergot DerivativesPrascend is contraindicated in any horse with a known hypersensitivity to ergot derivatives. Avoid pairing it with other ergot-alkaloid contaminated feedstuffs (like fescue grass infected with endophyte fungus), as this can compound vasoconstrictive or hormonal side effects.

Contraindications

Acepromozine

Government Numbers

Prascend pergolide 1 mg oral tablets: NADA 141-331. NDC 0010-4489-01 (60 tablets) and 0010-4489-02 (160 tablets). Labeler: Boehringer Ingelheim Animal Health USA Inc. These identifiers apply to Prascend tablets. Reviewed September 18, 2026. Full label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=455e5d97-f639-472b-b93b-88b9174a0310

Sanctioning-body comparison

Plasma only. Compare published competition guidance for this medication. ESC guidance remains in Medication Facts above. A dosing guideline, withdrawal recommendation and laboratory detection threshold are different measures.

Sources reviewed September 23, 2026. “Not verified” means a gap in this comparison, not zero tolerance or permission. Doses describe the cited rules; your veterinarian must determine treatment and withdrawal.

Published guidance by organization
OrganizationPublished dose & routePlasma concentrationWithdrawal / timingControl / penalty class
AQHA Show HorsesShow rules · 2026 handbook
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.
APHA Paint Show HorsesShow rules · 2026 Rule Book
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules.

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Medication-specific control not yet verified.
ARCI Model RulesRacing model · Rules 15 / UCG 20.0 / CTMS 4.2.1
Conditions & sources

An unverified entry is not permission to use this medication. Consult the linked current rules. ARCI model comparison only; no state-specific rule is substituted. Schedule timing is tied to its stated regimen and is not a clearance guarantee.

UCG 20.0 PDF p. 44

Reviewed 2026-09-23

Not verified for this medication.Not verified for this medication.Not verified for this medication.Drug Class 3 · Penalty Class B. No dosing permission is implied by classification.
USEFNational Therapeutic Substance Provisions · 2026 + July amendment
Conditions & sources

A TUE must be approved; merely applying is not permission. National USEF scope only.

Pergolide guidance; GR411

Reviewed 2026-09-23

No numeric dose specified in the TUE guidance.No numeric permitted plasma threshold stated.Approved pergolide TUE: no withdrawal; otherwise GR411 requires at least 24 h and MRF.Prohibited substance with a specific PPID TUE pathway.